News >

Onartuzumab Falters in Late-Stage NSCLC Trial

Silas Inman @silasinman
Published: Monday, Mar 03, 2014

Lung DiagramA phase III study exploring the MET inhibitor onartuzumab (MetMab) as a treatment for patients with non-small cell lung cancer (NSCLC) is being stopped, following an interim analysis that suggested a lack of clinically meaningful efficacy. Genentech, the company developing the drug, made the announcement on March 3.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication